than activity seen in vitro. PEGylation can be a phase advancement to widen the half-life while defending the natural activity of peptide and little protein drugs. These short-acting ... that can diminish pertinence to…
than activity seen in vitro. PEGylation can be a phase advancement to widen the half-life while defending the natural activity of peptide and little protein drugs. These short-acting ... that can diminish pertinence to…
dosing profiles that can reduce applicability to the clinic, particularly for chronic conditions. Therefore, half-life extension technologies are entering the clinic to enable improved or new biologic therapies…
estimate of half-life (t1/2) is of paramount importance in assessing the efficacy of drugs used to treat diabetes in patients. This study was conducted to develop Quantitative Structure ... using LOO method (p<0.005)…
Introduction: Half-life of drugs, useful substances( lab exams, calibrators, biomarkers), after the validation process, have the great application status in medical practice. Very important achieving to modify half-life…
factors that determine the occurrence and severity of drug interactions is the half-life of the drugs involved. Half-life refers to the time it takes for the concentration
monitored by a validated liquid-chromatography mass-spectrometric method and confirmed the very long half-life of the drug, which is estimated at 14.5 days. Conclusions: The pathophysiological mechanisms ... accumulate…
humic acid transformed into minerals product which involved the first orde reaction, 38.4 minute half-life, the constant rate of reaction is 0.02 minutes-1 and the quantum rendement
animal-derived organic wastes had higher biodegradation rate constants (k) as well as lower half-life times (t1/2) than soil microcosms amended with NPK fertilizer and unamended soil (natural
passing the CI being between times 24 and 120 h depending on Ka, half-life, and inter-subject variability. Based on this work, a reduction in the sampling duration ... data indicated a decrease and then an increase in…
There is poor patient compliance with daily dosing and novel strategies for improving pharmacokinetic half-life and potency are under development. Subcutaneously and intramuscularly administered recombinant human growth…
well designed as a drug carrier, including its high solubility and stability, long circulatory half-life and the potential to attach therapeutic candidates by fusion or conjugation. We will describe ... Veltis® albumin…
Short circulatory half-life represents a major obstacle for many protein and peptide-based therapeutic agents, resulting in increased dosing with the consequent risk of side effects and reduced patient ... significantly…